



## OpGen to Present at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference

February 3, 2016

GAITHERSBURG, Md., Feb. 03, 2016 (GLOBE NEWSWIRE) -- **OpGen, Inc.** (NASDAQ:OPGN), a precision medicine company using molecular diagnostics and bioinformatics to combat infectious disease, announces that Evan Jones, the Company's Chairman and Chief Executive Officer, will present at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference on February 11, 2016 at 2:45 p.m. Eastern time. The conference is being held from February 10 to 11 in New York City.

To listen to the presentation live, investors may visit the investor relations section of OpGen, Inc.'s website at [www.opgen.com](http://www.opgen.com). An archived audio of the presentation will also be available on OpGen's website for 90 days.

### About OpGen, Inc.

OpGen, Inc. (NASDAQ:OPGN) is developing and deploying precision medicine tools to combat infectious disease in global healthcare settings, helping to guide clinicians with more rapid information about life threatening infections, improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen offers a full portfolio of in vitro diagnostic products and clinical laboratory services that employ state-of-the-art molecular diagnostics and bioinformatics. Its *QuickFISH*<sup>™</sup> products are a suite of FDA-cleared and CE-marked diagnostics used to rapidly detect pathogens in positive blood cultures. Clinical laboratory services utilize the Acuitas<sup>®</sup> products, including the MDRO Gene Test, the Resistome Test, microbial Whole Genome Sequence Analysis, and Acuitas Lighthouse<sup>™</sup> MDRO Management System designed to detect, type, track, and trend antibiotic resistant organisms in real-time. Learn more at [www.opgen.com](http://www.opgen.com).

### Contacts:

#### OpGen

Michael Farmer  
Director, Marketing  
(240) 813-1284  
[mfarmer@opgen.com](mailto:mfarmer@opgen.com)  
[InvestorRelations@opgen.com](mailto:InvestorRelations@opgen.com)

#### Investors

LHA  
Kim Sutton Golodetz  
(212) 838-3777  
[kgolodetz@lhai.com](mailto:kgolodetz@lhai.com)  
or  
Bruce Voss  
(310) 691-7100  
[bvoss@lhai.com](mailto:bvoss@lhai.com)



OpGen, Inc.